Clinical Trials Browser

Phase 2 × Carboplatin × Gynecologic × Clear all

NCT05952453 2026-03-11

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Phase 2 Recruiting

Ovarian Neoplasms

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT04415944 2026-02-27

HIPEC

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07432594 2026-02-25

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Phase 2 Not yet recruiting

Fallopian Tube Neoplasms

NCT06890338 2026-02-24

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Ovarian Neoplasms

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

GynecologicSarcoma

Advanced Endometrial Cancer

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT02001272 2025-12-19

EWOC-1

Phase 2 Completed

Ovarian Neoplasms

NCT07285941 2025-12-16

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

Phase 2 Recruiting

Ovarian Neoplasms

NCT06561308 2025-12-01

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Phase 2 Recruiting

Endometrioid Endometrial Cancer

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03188432 2025-10-21

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

50 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02730416 2025-07-29

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

NCT01244789 2025-07-23

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05605535 2025-07-11

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07022535 2025-07-02

PRESELECT-0

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07023484 2025-07-02

Preselect-1

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04527900 2025-06-19

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

Phase 2 Terminated

Endometrial Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02520154 2025-06-08

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

31 enrolled 12 charts

Fallopian Tube Neoplasms

NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

NCT04274426 2025-04-06

MIROVA

Phase 2 Active not recruiting

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2 Completed

38 enrolled 12 charts

Endometrial Neoplasms

NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Phase 2 Completed

50 enrolled 14 charts

Recurrent Endometrial Endometrioid Adenocarcinoma

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT05932212 2025-03-12

AK104 for Recurrent or Metastatic Vulvar Cancer

Phase 2 Recruiting

Vulvar Neoplasms

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Phase 2 Not yet recruiting

Recurrence, Endometrial Neoplasms

NCT06437353 2024-11-27

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT02124421 2024-11-19

CRS/HIPEC

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06522828 2024-10-21

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Phase 2 Recruiting

Endometrial Neoplasms

NCT01696032 2024-08-27

SGI-110

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT06419673 2024-05-17

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT05080556 2024-04-12

ACTOv

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03189446 2024-03-08

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer

Phase 2 Completed

39 enrolled 8 charts

Endometrial Neoplasms

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT01001910 2024-02-28

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

22 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02766582 2024-02-26

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Phase 2 Completed

29 enrolled 9 charts

Ovarian Neoplasms